Shots:
- The companies collaborated to develop improved tissue-selective AAV vectors to realize effective gene therapy treatments for multiple life-threatening disorders
- The focus of this agreement is to develop new and modified AAV capsids that exhibit a safe product profile with improved specificity and higher gene delivery efficiency
- The collaboration comes two years after Sirion signed a similar pact with Denali Therapeutics, with other partners including Acucela and Orchard Therapeutics
Click here to read full press release/ article | Ref: Businesswire | Image: Businesswire
The post Sanofi Collaborates with Sirion to Develop Gene Therapy Treatment with Improved AAV Capsids first appeared on PharmaShots.
